Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329

Watchlist Manager
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Logo
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Watchlist
Price: 44.48 CNY 1.32% Market Closed
Market Cap: ¥34.3B

Relative Value

The Relative Value of one Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 44.48 CNY, Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
34.3B CNY 6.4 9.6 42.2 42.2
US
Eli Lilly and Co
NYSE:LLY
978.7B USD 16.5 53.2 35.7 38.3
US
Johnson & Johnson
NYSE:JNJ
547.3B USD 5.8 20.4 14.2 17.5
CH
Roche Holding AG
SIX:ROG
277.3B CHF 4.5 29.4 12.5 14.6
UK
AstraZeneca PLC
LSE:AZN
210B GBP 4.9 30.2 19.7 28.8
CH
Novartis AG
SIX:NOVN
220.8B CHF 5 19.4 15.6 20.1
US
Merck & Co Inc
NYSE:MRK
273B USD 4.3 14.4 10.2 12.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.9 11.1 12.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
150.2B USD 2.4 15.3 7.7 10.5
FR
Sanofi SA
PAR:SAN
95.7B EUR 1.7 8 7.6 7.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Average EV/EBITDA: 47.4
42.2
33%
1.3
US
Eli Lilly and Co
NYSE:LLY
35.7
34%
1
US
Johnson & Johnson
NYSE:JNJ
14.2
2%
7.1
CH
Roche Holding AG
SIX:ROG
12.5
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
19.7
10%
2
CH
Novartis AG
SIX:NOVN
15.6
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
1%
11.1
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
0%
N/A
FR
Sanofi SA
PAR:SAN
7.6
8%
0.9